Literature DB >> 22231797

Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.

Shun-ichi Chitose1, Hideki Chijiwa, Akiteru Maeda, Hirohito Umeno, Tadashi Nakashima, Kensuke Kiyokawa, Naofumi Hayabuchi, Hiromasa Fujita.   

Abstract

The aim of this study is to clarify the prognostic value of the pathological overall tumor cellularity after neoadjuvant chemotherapy for locally advanced hypopharyngeal cancer. In consecutive series of 45 operable patients with locally advanced hypopharyngeal cancer, neoadjuvant chemotherapy by cisplatin and 5-fluorouracil was administered. Pathological image analysis was performed in 30 patients using the large cross-section specimen after total resection to evaluate the overall tumor cellularity. The chemotherapeutic responses were classified according to the pathological grading scale by dividing into four categories; more than 70% overall tumor cellularity in Grade 1, between an estimated 10 and 70% in Grade 2, less than 10% in Grade 3, and no identifiable malignant tumor cells in Grade 4. The pathological grades were taken into account for analysis of the survival. In 30 available patients, 40% had Grade 1 pathological response, 30% had Grade 2, and 30% had Grade 3. There was no Grade 4 patient. The overall 5-year survival rate for these 30 patients was 53.33%. The survival rate (61.66%) for patients with Grade 2 and 3 responses was significantly higher than that (27.78%) for patients with Grade 1 response (p = 0.009). Cox regression analysis revealed that the increasing pathological grade was an independent predictor of a better survival in patients undergoing neoadjuvant chemotherapy. We have shown that the prognosis of patients with locally advanced hypopharyngeal cancer, who had been treated by neoadjuvant chemotherapy followed by total resection, can be predicted by evaluation of pathological overall tumor cellularity from the large section specimen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231797     DOI: 10.1007/s00405-011-1915-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  21 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

Authors:  J L Lefebvre; D Chevalier; B Luboinski; A Kirkpatrick; L Collette; T Sahmoud
Journal:  J Natl Cancer Inst       Date:  1996-07-03       Impact factor: 13.506

4.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.

Authors:  D M Sataloff; B A Mason; A J Prestipino; U L Seinige; C P Lieber; Z Baloch
Journal:  J Am Coll Surg       Date:  1995-03       Impact factor: 6.113

5.  Tumor volume as determined by computed tomography predicts local control in hypopharyngeal squamous cell carcinoma treated with primary surgery.

Authors:  Marc Keberle; Florian Hoppe; Silke Dotzel; Dietbert Hahn
Journal:  Eur Radiol       Date:  2003-07-05       Impact factor: 5.315

6.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

Review 7.  Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.

Authors:  Sunati Sahoo; Susan C Lester
Journal:  Arch Pathol Lab Med       Date:  2009-04       Impact factor: 5.534

8.  Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

Authors:  Jianzhou Wang; Thomas A Buchholz; Lavinia P Middleton; D Craig Allred; Susan L Tucker; Henry M Kuerer; Francisco J Esteva; Gabriel N Hortobagyi; Aysegul A Sahin
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

9.  Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.

Authors:  T Nishimura; K Newkirk; R B Sessions; P A Andrews; B J Trock; A A Rasmussen; E A Montgomery; E K Bischoff; K J Cullen
Journal:  Clin Cancer Res       Date:  1996-11       Impact factor: 12.531

10.  Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).

Authors:  C Domenge; C Hill; J L Lefebvre; D De Raucourt; B Rhein; P Wibault; P Marandas; B Coche-Dequeant; M Stromboni-Luboinski; H Sancho-Garnier; B Luboinski
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  1 in total

1.  Pyriform sinus squamous cell carcinoma: oncological outcomes in good responders of induction chemotherapy-based larynx preservation protocols.

Authors:  Zacharias Vourexakis; Anne-Marie Le Ridant; Pavel Dulguerov; François Janot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-23       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.